Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD
A meta-analysis of 14 trials (6,412 patients) found endothelin receptor antagonists reduced the risk of kidney failure and proteinuria in chronic kidney disease, though they raised the risk of low blood pressure.
Category
Research
Source
Clinical Journal of the American Society of Nephrology (CJASN)
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.